Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Robust Analytical Methods for Successful Lentiviral Vector IMPDs

EXECUTIVE SUMMARY

Programmatic Asset

CELL & GENE | RNA | BIOLOGICS

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

For biotech sponsors targeting European markets, a robust analytical package for lentiviral (LV) vectors is the foundation of a successful Investigational Medicinal Product Dossier (IMPD). This requires moving beyond basic titer measurements to a comprehensive characterization of vector identity, purity, potency, and safety. A phase-appropriate analytical strategy, executed in a GxP environment, directly supports regulatory acceptance by demonstrating product consistency and control, which helps de-risk the path to clinical evaluation.

Frequently Asked Questions

What are the most important analytical assays for a lentiviral vector IMPD submission to European authorities?

For an IMPD, regulators expect a comprehensive analytical data package. Key assays include vector genome titer (by qPCR or ddPCR), p24 capsid protein quantification, vector identity confirmation via sequencing, assessment of process-related impurities like host cell proteins and residual DNA, and a functional potency assay to measure biological activity. A replication-competent lentivirus (RCL) assay is also a required safety test.

How does Franklin Biolabs ensure analytical methods for LV characterization are suitable for GxP environments?

We develop and qualify all analytical methods in a phase-appropriate manner. As a program advances toward clinical trials, the assays used to characterize the lentiviral vector undergo increasing levels of validation to meet GxP requirements. This ensures the data is reliable, reproducible, and suitable for inclusion in regulatory filings like an IMPD or IND.

How does vector copy number (VCN) inform the safety and efficacy profile of a lentiviral vector?

Vector copy number is a measure of the average number of vector integrations into the host cell genome. For LV vectors, VCN is a key quality attribute (CQA) that directly correlates with both therapeutic efficacy and potential safety risks like insertional mutagenesis. Precise VCN measurement helps define the product’s dose and safety profile in regulatory submissions.

Analytical Characterization of Lentiviral Vectors for IMPD Submissions

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

A scientist in protective gear pipetting a sample into a vial within a sterile laboratory hood.

A Multi-Attribute Approach to Vector Control for European Submissions.

Characterizing lentiviral vectors for an Investigational Medicinal Product Dossier (IMPD) requires a distinct analytical strategy. The permanent nature of LV transduction necessitates a deep level of scrutiny into vector copy number, integration site profiles, and the potential for replication competence. A successful IMPD submission hinges on a data package that demonstrates a profound understanding and control over these key quality attributes.

The analytical methods must be sufficiently sensitive and specific to define the product’s identity, quantity, purity, potency, and safety. The scientific basis for the entire clinical program is established through this comprehensive analytical profile. Our approach focuses on building this profile to anticipate and address the specific questions posed by European regulatory bodies.

Integrated Methods for Vector Definition

Defining a lentiviral vector product requires the integration of orthogonal methods to build a complete profile of the vector lot. A robust characterization plan provides a multi-faceted view of the therapeutic article.

  • Vector Titer & Quantity: We employ both qPCR/ddPCR for vector genome titer and p24 ELISA for capsid protein concentration. Correlating these values provides insight into the ratio of full to empty particles.

  • Identity & Integrity: Next-generation sequencing (NGS) is used to confirm the integrity of the vector’s genetic material, including the promoter, transgene, and other elements, ensuring no unintended mutations arose during production.

  • Potency: A well-defined, cell-based potency assay is developed to measure the biological function of the vector. This assay becomes a cornerstone of the quality control strategy for lot release.

  • Purity & Residuals: Analysis of process-related impurities, such as host cell proteins and residual plasmid DNA, is performed to ensure the final product meets stringent purity specifications.

This multi-parametric approach provides the consistency data required for regulatory confidence. Our extensive experience is reflected in our client feedback: “Wonderful services. Excellent team to work with. Vast knowledge in all aspects of vector production and analytics.”

A scientist in a lab coat and gloves loads samples into a ProteinSimple instrument for analysis.

Linking Vector Design to In Vivo Performance

Rigorous analytical characterization provides sponsors with data that helps predict how a therapeutic will behave in a clinical setting. By meticulously defining the vector’s attributes at the molecular level, we establish a direct link between the product’s quality profile and its expected biological performance, supporting an 18-24 month timeline to IND.

This analytical rigor is executed across our >100,000 sq ft of specialized laboratory and GxP-compliant facilities. The data generated forms the core of the CMC section of an IMPD, providing regulators with the assurance that the manufacturing process is well-controlled and capable of producing a consistent product.

This detailed characterization is a core component of our work, which is further detailed in our primary Vector | CMC | Analytics Services offerings.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities